ER+ breast cancer patients whose tumors have low ODx Recurrence Scores (RS) do well with adjuvant hormonal therapy alone, while tumors with high ODx RS are more likely to benefit from the addition of chemotherapy to hormonal therapy. This evidence concerns the gene ESR1 and breast cancer.